Cuộc họp công bố kết quả kinh doanh Quý 2/2026 của MaxCyte (MXCT): Tái khẳng định dự báo khi quan hệ hợp tác với Genentech mở rộng

Điểm tin chính

• MaxCyte đã báo cáo tổng doanh thu quý 2/2026 đạt 7,3 triệu USD, giảm 15% so với cùng kỳ năm trước, bao gồm 6,5 triệu USD doanh thu cốt lõi và 0,8 triệu USD doanh thu liên quan đến chương trình SPL.
• Doanh thu cốt lõi giảm 21%, phản ánh doanh thu cấp phép thấp hơn từ các chương trình đối tác bị chấm dứt, thời điểm bàn giao thiết bị và mức nền so sánh cao của các cụm xử lý do hoạt động mua hàng liên quan đến thuế quan trong quý 2/2025.
• Chi phí hoạt động giảm 25% xuống 15,8 triệu USD, phản ánh đầy đủ lợi ích từ các biện pháp tái cấu trúc và tối ưu hóa chi phí được triển khai trong năm 2025.
• MaxCyte đã tái khẳng định dự báo doanh thu năm 2026 từ 30 triệu đến 32 triệu USD và kỳ vọng doanh thu tăng trưởng ở mức một chữ số thấp so với cùng kỳ năm trước trong nửa cuối năm.
• Quan hệ đối tác mới với Genentech giới thiệu mô hình đa nền tảng ở cấp độ doanh nghiệp, bao phủ nhiều chương trình từ nghiên cứu đến sản xuất cGMP. Ban lãnh đạo cho biết mô hình này bổ sung chứ không thay thế các thỏa thuận SPL truyền thống.
• MaxCyte kết thúc quý 2 với 141,9 triệu USD tiền, các khoản tương đương tiền và đầu tư, không có nợ, và đã mua lại khoảng 5,5 triệu USD cổ phiếu theo hạn mức 10 triệu USD được phê duyệt tính đến thời điểm cuộc họp.

Dữ liệu tài chính quan trọng

Kết quả hoạt động kinh doanh và vận hành

Số lượng thiết bị được bàn giao tăng so với quý trước ở các ứng dụng nghiên cứu, phát triển quy trình và lâm sàng. Ban lãnh đạo ghi nhận việc ứng dụng sớm nền tảng ExPERT DTx cùng với việc tiếp tục bàn giao các thiết bị GTx cho các khách hàng công nghệ sinh học và viện nghiên cứu, cũng như thiết bị STx cho phát triển quy trình.

Công ty kỳ vọng mức độ ứng dụng DTx sẽ gia tăng trong phần còn lại của năm 2026 và sang năm 2027. DTx tương thích với nền tảng ExPERT mở rộng, cho phép khách hàng chuyển từ giai đoạn phát hiện sang các hệ thống STx và GTx để sản xuất cGMP. Ban lãnh đạo cũng cho biết DTx sẽ thúc đẩy nhu cầu sử dụng cụm xử lý cao hơn trong các quy trình nghiên cứu giai đoạn đầu.

Thỏa thuận với Genentech cung cấp quyền truy cập vào ExPERT GTx, công nghệ chuyển gen bằng xung điện (electroporation) và các công nghệ đánh giá phân tích trong nghiên cứu, phát triển lâm sàng và sản xuất. Thỏa thuận này hỗ trợ nhiều chương trình trong một khuôn khổ doanh nghiệp duy nhất, bao gồm hai chương trình dị ghép lâm sàng và một chương trình nghiên cứu tiền lâm sàng. Các cơ hội doanh thu bao gồm phí cấp phép định kỳ, quyền truy cập nền tảng, thiết bị, cụm xử lý, công nghệ phân tích và các khoản thanh toán theo cột mốc.

MaxCyte hiện có 30 đối tác cấp phép, bao gồm 29 đối tác SPL và đối tác doanh nghiệp Genentech. Ban lãnh đạo cho biết 5 chương trình đối tác có thể bắt đầu thương mại hóa trong vài năm tới, sớm nhất là vào năm 2027, đồng thời nhấn mạnh rằng mỗi chương trình đều tiềm ẩn rủi ro lâm sàng và thương mại.

Doanh thu liên quan đến chương trình SPL được hưởng lợi từ tiền bản quyền CASGEVY. Vertex đã báo cáo doanh thu CASGEVY trong quý 2/2026 đạt khoảng 76 triệu USD, tăng khoảng 75% so với quý trước và 150% so với cùng kỳ năm trước. MaxCyte đã ghi nhận 1,2 triệu USD doanh thu tiền bản quyền trong nửa đầu năm, bao gồm 0,8 triệu USD trong quý 2.

SeQure duy trì đà tăng trưởng tích cực so với cùng kỳ năm trước. Ban lãnh đạo tiếp tục kỳ vọng doanh thu từ dịch vụ xét nghiệm SeQure và cấp phép sẽ tăng trưởng trong năm 2026.

Dự báo của Ban lãnh đạo

MaxCyte đã tái khẳng định triển vọng năm 2026 như sau:

• Tổng doanh thu: 30 triệu đến 32 triệu USD
• Doanh thu cốt lõi: 25 triệu đến 27 triệu USD
• Các khoản thanh toán theo cột mốc và tiền bản quyền SPL: 5 triệu USD, bao gồm 3 triệu USD từ các cột mốc và 2 triệu USD tiền bản quyền
• Tăng trưởng doanh thu nửa cuối năm: Ở mức một chữ số thấp so với cùng kỳ năm trước
• Biên lợi nhuận gộp: Trong khoảng 75% trong nửa cuối năm
• Chi phí hoạt động: Dự kiến sẽ không tăng đáng kể so với mức hiện tại
• Tiền, các khoản tương đương tiền và đầu tư cuối năm: Ít nhất 130,5 triệu USD, không bao gồm nguồn vốn bổ sung được triển khai theo chương trình mua lại cổ phiếu

Ban lãnh đạo kỳ vọng doanh thu quý 4 sẽ cao hơn một chút so với quý 3 do ngân sách chi tiêu cuối năm theo thông lệ của khách hàng. Việc bàn giao thiết bị được dự báo sẽ là động lực tăng trưởng chính, cùng sự hỗ trợ từ doanh thu cấp phép ổn định, nhu cầu cụm xử lý, hợp tác với Genentech và việc tiếp tục triển khai DTx.

Rủi ro và các yếu tố cần theo dõi

Doanh thu cốt lõi vẫn thấp hơn so với cùng kỳ năm trước sau khi các chương trình lâm sàng của đối tác bị chấm dứt và khách hàng lớn nhất của MaxCyte cắt giảm hàng tồn kho. Ban lãnh đạo cho biết quá trình giải phóng hàng tồn kho về cơ bản đã hoàn tất và không ảnh hưởng đến nửa cuối năm, nhưng nhu cầu cụm xử lý trong tương lai vẫn gắn liền với tiến độ chương trình của đối tác.

Biên lợi nhuận gộp dự kiến vẫn thấp hơn so với năm trước do thiết bị chiếm tỷ trọng doanh thu lớn hơn so với các khoản cấp phép có biên lợi nhuận cao hơn.

Ban lãnh đạo mô tả nguồn vốn cho liệu pháp tế bào ở mức ổn định chứ không quay trở lại mức của giai đoạn 2020–2021. Do đó, chiến lược tăng trưởng của công ty phụ thuộc một phần vào việc đa dạng hóa doanh thu thông qua sản phẩm mới, khách hàng viện nghiên cứu, hợp tác với các tập đoàn dược phẩm lớn và các dịch vụ phân tích.

Doanh thu tiền bản quyền có thể biến động theo từng quý khi quá trình thương mại hóa CASGEVY phát triển. Các chương trình đối tác cũng tiếp tục chịu sự tác động từ các rủi ro lâm sàng, pháp lý và thương mại.

Nội dung nổi bật từ phần Hỏi & Đáp với chuyên gia phân tích

• Nhu cầu thiết bị: Ban lãnh đạo cho biết việc bàn giao thiết bị đã cải thiện trên toàn bộ danh mục sản phẩm và không còn thấy sự suy yếu ở mảng chi tiêu vốn. Phễu bán hàng bao gồm các khách hàng nghiên cứu và doanh nghiệp, trong đó Genentech và DTx dự kiến sẽ đóng góp vào nửa cuối năm.
• Các hợp tác doanh nghiệp trong tương lai: MaxCyte đang thảo luận về các thỏa thuận tương tự với các công ty dược phẩm lớn khác. Ban lãnh đạo lưu ý rằng các cuộc đàm phán có thể kéo dài 18 tháng hoặc lâu hơn.
• Danh mục dự án SPL: Công ty tiếp tục coi 3 đến 5 thỏa thuận cấp phép mỗi năm là mức trung bình dài hạn hợp lý và cho biết có thể ký 1 đến 2 thỏa thuận trong nửa cuối năm, bao gồm Genentech.
• Thời điểm thực hiện chương trình đối tác: Ban lãnh đạo kỳ vọng tác động lớn hơn từ 5 chương trình giai đoạn cuối sẽ tập trung vào năm 2027 hơn là nửa cuối năm 2026.
• Phân bổ vốn: Đầu tư tự thân vẫn là ưu tiên hàng đầu, tiếp theo là các giao dịch tiềm năng có chọn lọc và mang lại lợi nhuận cho cổ đông. Khoảng 5,5 triệu USD trong chương trình mua lại cổ phiếu trị giá 10 triệu USD được phê duyệt đã được thực hiện tính đến thời điểm cuộc họp.
• Mở rộng tại Châu Á - Thái Bình Dương: MaxCyte đang đầu tư vào Trung Quốc, Nhật Bản, Hàn Quốc, Ấn Độ và Úc, được hỗ trợ bởi đội ngũ bán hàng khu vực, ứng dụng khoa học thực địa và quản lý. Công ty hướng tới việc chuyển đổi các mối quan hệ lâm sàng giai đoạn đầu thành các thỏa thuận SPL và hợp tác trong tương lai.

Toàn văn Biên bản Cuộc họp Báo cáo Kết quả Kinh doanh

Toàn văn cuộc gọi công bố kết quả kinh doanh

Phần trình bày của ban lãnh đạo

Operator

Good day, and thank you for standing by. Welcome to the MaxCyte Second Quarter Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Eric Abdill of Investor Relations. Please go ahead.

Eric Abdill

Good afternoon, everyone. Thank you for participating in today's conference call. Joining me on the call from MaxCyte, we have Maher Masoud, President and Chief Executive Officer; Parmeet Ahuja, Chief Financial Officer; and Sean Menarguez, Senior Director of Business Development. Earlier today, MaxCyte released financial results for the second quarter ended June 30, 2026. A copy of the press release is available on the company's website.

Before we begin, I need to read the following statement. Statements or comments made during this call may be forward-looking statements within the meaning of federal securities laws. Any statements contained in this call other than statements of historical fact, including those that relate to expectations or predictions of future events, results, or performance, are forward-looking statements. Actual results may differ materially from those expressed or implied in any forward-looking statements due to a variety of factors, which are discussed in detail in our SEC filings.

Except as required by applicable law, the company has no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. And with that, I will turn the call over to Maher.

Maher Masoud

Thank you, Eric. Good afternoon, everyone, and thank you for joining MaxCyte's Second Quarter 2026 Earnings Call. MaxCyte reported $7.3 million of total revenue in the second quarter, including $6.5 million of core revenue and $0.8 million of SPL program-related revenue, which consists of milestones and royalties. Results were ahead of our expectations and consistent with the framework we laid out coming into the year.

As expected, we entered 2026 facing several headwinds, including inventory drawdown by our largest customer and headwinds resulting from the discontinuation of a few partner clinical programs last year. Despite those challenges, our objective was clear: stabilize revenue in the first half and return to growth in the second half. Our first half results reflect the stabilization where both our Q1 and Q2 revenues were ahead of our expectations, and we remain confident in our ability to achieve our goal of returning to growth in the back half of the year.

We achieved sequential revenue growth in Q2 compared to Q1, primarily driven by instrument placements across our portfolio, including our recently launched DTx platform. We also continue to see GTx placement across biotech and academic customers, reflecting ongoing program advancement. Processing assembly revenue remained stable sequentially, supported by SPL portfolio. The second quarter reflected disciplined execution against our operating plan, resulting in improved first half financial results.

We delivered a meaningful reduction in net loss year-over-year despite the revenue headwinds we faced heading into 2026, and we expect to build on that progress as we execute against our plan and return to revenue growth. Furthermore, we have continued to invest in R&D priorities that expand our platform and strengthen our long-term growth opportunities.

Investments in ExPERT DTx, SeQure and newer strategic collaborations are designed to broaden how we engage with customers from early discovery through clinical development and commercial manufacturing while further diversifying MaxCyte's revenue streams over time. Additionally, I want to highlight a significant milestone for the company as we recently announced our multi-platform technology license partnership with Genentech, which we believe reflects the growing recognition of MaxCyte's technology across the ecosystem from early research all the way through commercial manufacturing.

Under the agreement, MaxCyte provides Genentech with access to our ExPERT GTx platform and additional platform technologies, including our electroporation and analytical assessment capabilities across research, clinical development and manufacturing workflows. The partnership is structured to support multiple programs and to enable Genentech's ex vivo cell engineering activities from early discovery through cGMP manufacturing. I want to be clear about why I believe this agreement is so important for MaxCyte.

It is an evolution in how we partner with the largest players in our industry. Rather than licensing our technology on a single program basis, we have established an enterprise-level relationship with Genentech that supports multiple cell therapy programs under a single framework. We believe this structure reflects how large pharmaceutical organizations increasingly want to deploy enabling technologies as enterprise-wide platforms that support multiple programs. We expect this trend will allow MaxCyte to participate more broadly across the development life cycle of a customer's portfolio, not just one product at a time.

The result is multiple platforms being used across a portfolio of programs rather than just for one program. We structured the partnership with Genentech with the goal of creating long-term value for MaxCyte while shifting a greater proportion of that value earlier in the customer life cycle. We expect that will mean greater revenue capture during research and clinical development across many of our platforms, durable recurring license and platform access revenue, complemented by milestone-based opportunities and continued demand for our instruments, processing assemblies and analytical technologies.

The agreement also provides participation in commercial manufacturing through annual licensing and platform realization. While the structure differs from a traditional SPL, we believe the risk-adjusted economics are more favorable on a partnership level given the enterprise portfolio-based relationship across the entire development life cycle. This enterprise-based model monetizes multiple revenue streams across the customer relationship while reducing our dependence on the outcome of any single clinical program. This agreement structure complements our SPL model. It does not replace it.

We believe SPLs remain the right commercial solution for many of our biotech customers who are developing individual therapeutic programs, and we expect to continue selling SPLs going forward. Over the past several years, we have consistently maintained strong royalty-based economics across our SPL partnerships and our current pipeline gives us confidence in our ability to continue doing so, reflecting the value of our offering to cell and gene therapy developers. Our existing SPL agreements continue under the contractual terms, including acquired entity provisions where applicable.

Our pipeline continues to support attractive royalty-based SPL opportunities, and we expect both commercial models to coexist, each serving different customer needs. Beyond our relationship with Genentech, we believe this partnership establishes a commercial framework that can be applied with other large pharmaceutical organizations over time. It helps validate the breadth and strength of MaxCyte's technology portfolio, expand our addressable market within large pharma and demonstrate our ability to engage a leading global biopharmaceutical company at an enterprise level. Overall, I am very excited about what this partnership represents for MaxCyte and about the opportunities it creates for the future.

On the instrument side, ExPERT DTx adoption continues to build with encouraging early traction across discovery and early optimization workflows in both ex vivo and in vivo cell and gene therapy. As I've discussed on prior calls, the DTx is fully compatible with the rest of our ExPERT platform, which gives customers who adopt the instrument in discovery a seamless path to scale on our STx and GTx instruments for cGMP manufacturing and ultimately into a partnership agreement.

We expect DTx adoption to build through the balance of 2026 and into next year. We also continue to see steady progress with SeQure in the quarter. The regulatory environment continues to evolve in our favor, and we continue to expect year-over-year growth for SeQure assay services and licenses in 2026. We firmly believe that SeQure assays will become part of the industry standard for off-target risk assessment and gene editing. Turning to SPL program-related revenue. We recognized $0.8 million in the second quarter, which was comprised of nearly all royalties. Vertex reported approximately $76 million of CASGEVY revenue for the second quarter of 2026, reflecting approximately 75% sequential growth versus Q1 2026 and 150% year-over-year growth.

On its earnings call, Vertex noted that more CASGEVY infusions were completed in the first half of 2026 than in all of 2025. Additionally, Vertex also indicated that more than 100 patients initiated their treatment journey for CASGEVY during the second quarter, which marked the third consecutive quarter with more than 100 patient initiations. They also noted that regulatory submissions for CASGEVY are now complete in Saudi Arabia and the U.K. in the 5 to 11 age group, and they are seeing continued strong uptake in the U.K., Italy and Middle East.

Overall, we remain very encouraged by CASGEVY's continued commercial trajectory, and we truly believe in its long-term transformative potential for patients. Turning to our customers. We have 30 total license partnerships, which includes 29 SPL partners and our recently announced multi-platform enterprise partnership with Genentech. We continue to see encouraging progression across our partner pipeline with multiple clinical stage programs moving towards late-stage development. Importantly, we have five partner programs with the potential to begin commercial launches in the next couple of years, including as early as next year.

While any individual program carries clinical or commercial risk, we believe the breadth and diversification of our multiple shots on goal give us a high probability of generating meaningful core revenue, regulatory milestones and commercial royalties over time. Our SPL portfolio remains a key driver of long-term value as is evident by the growing commercial royalty revenue and the advancement of a significant number of SPL programs through the clinic. Looking to the second half of the year, we remain confident in our return to revenue growth.

We expect growth to be driven primarily by instrument placements, supported by stable license revenue and processing assembly demand from our SPL partners, including our recently announced partnership, the continued rollout of ExPERT DTx and a healthy commercial funnel across both new and existing customers. On the processing assembly side, a significant portion of the inventory drawdown from our largest customer is now behind us. We expect stable processing assembly demand as the SPL-related program headwinds we experienced in the first half also have largely subsided.

Taken together, these factors give us strong confidence in our outlook for 2026. To close, I am pleased with the execution of our team in the second quarter. The Genentech partnership agreement represents a meaningful step forward in how we engage with our customers and reinforces the growing role our platform plays across the cell and gene therapy ecosystem. We are proud of our accomplishments and our positioning for long-term growth and plan to continue to invest in the business with financial and commercial discipline as we execute in the second half of 2026 and beyond. I will now turn the call over to Parmeet. Parmeet?

Parmeet Ahuja

Thank you, Maher. Total revenue in the second quarter of 2026 was $7.3 million compared to $8.5 million in the second quarter of 2025, representing a 15% decrease. We reported core revenue of $6.5 million compared to $8.2 million in the comparable prior year quarter, representing a 21% decrease. Within core revenue, instrument revenue was $1.8 million compared to $2.1 million in the second quarter of 2025.

License revenue was $1.8 million compared to $2.6 million in the second quarter of 2025, and processing assembly, or PA, revenue was $2.3 million compared to $3.1 million. Core revenue in the second quarter was primarily impacted by lower license revenue due to discontinued partner programs, the timing of instrument placements and a difficult year-over-year comparison driven by PA purchases in the second quarter of 2025 that were accelerated by tariff-related dynamics. Excluding these one-time tariff-driven purchases, PA revenue was relatively flat year-over-year, reflecting a stabilization in activity across our customer base.

SeQure saw continued positive year-over-year momentum in the quarter with total revenue of $0.5 million, which includes both license and services revenue. SPL program-related revenue in the second quarter was $0.8 million, consisting almost entirely of royalty revenue compared to $0.3 million of SPL program-related revenue in the second quarter of 2025. The year-over-year increase reflects continued growth in royalty revenue as CASGEVY adoption and commercial sales continue to build. Moving down the P&L. Gross margin was 77% in the second quarter of 2026 compared to 82% in the second quarter of 2025.

Excluding inventory provisions and SPL program-related revenue, non-GAAP adjusted gross margin was 77% in the second quarter of 2026 compared to non-GAAP adjusted gross margin of 83% in the second quarter of 2025. Gross margin for the quarter was primarily impacted by product mix, driven by a higher proportion of instrument revenue, which carries lower gross margins than our licenses. Looking forward and as discussed on last quarter's call, we expect these trends to continue in the back half of the year with gross margins in the mid-70s. Total operating expenses for the second quarter of 2026 were $15.8 million compared to $21.2 million in the second quarter of 2025, a decrease of approximately $5 million or 25%.

We continue to remain disciplined in managing our cost structure. The reduction in operating expenses reflects the full run rate benefit of the restructuring and cost efficiency actions we took in 2025, which are now being realized across the P&L. Looking forward, we do not expect operating expenses to grow meaningfully from these current levels, even though we continue to make investments in product development, which we believe will contribute to our continued return to growth. As revenue growth returns in the second half of the year, we expect the combination of disciplined cost management and revenue growth to further reduce cash burn.

We ended the second quarter with combined total cash, cash equivalents and investments of $141.9 million and no debt. Last quarter, we announced the Board's authorization of a $10 million share repurchase program. As previously indicated, we intend to execute the majority of the program before year-end. Since the authorization, we have repurchased approximately $5.5 million of MaxCyte's stock as of today. Our balance sheet is well positioned moving forward, enabling us to continue to invest strategically in our business.

Continuing to our 2026 guidance. We are reiterating our 2026 outlook and expect total revenue to be in the range of $30 million to $32 million, consisting of $25 million to $27 million of core revenue and $5 million of SPL milestones and royalties. For the back half of 2026, we expect low single-digit year-over-year revenue growth. On the quarterly cadence, we expect usual seasonality with Q4 being slightly higher than Q3, driven by typical year-end budget flush dynamics.

For SPL milestones and royalties guidance, we expect $3 million of revenue from milestones and $2 million of royalty revenues, with $3 million of milestone revenue already received in Q1. Lastly, we anticipate ending 2026 with at least $130.5 million in cash, cash equivalents and investments, excluding any further capital deployed towards our repurchase program. Now I'll turn the call back over to Maher.

Maher Masoud

Thank you, Parmeet, and thank you to everyone at MaxCyte for their hard work and dedication each and every day to move our company and mission forward. I look forward to updating you on our next quarterly call. With that, I will turn the call back over to the operator for the Q&A. Operator?

Operator

[Operator Instructions] And our first question comes from the line of Julie Simmonds of Panmure Liberum.

Phần hỏi đáp

Julie Simmonds

I suppose a couple of questions. Firstly, on the step-up in instrument revenue, which is slightly higher than I was looking for. I was just wondering whether you could give any sort of indication as to where that's coming from, particularly in terms of your instrument portfolio?

And then secondly, just on the guidance on the non-core business revenue. That looks a little bit low to me given what you've already received in milestones and also the run rate that Vertex is demonstrating currently. Any reasons why you haven't changed that yet?

Maher Masoud

Sure. Let me take the first one, Julie, and then -- Parmeet, if you want to take the second part of the question. On the instrument side, Julie, it was across the board. We saw it in research, process development and clinical as well. So there's not any one particular -- it's a product mix. We saw some early traction with DTx, continued traction in the clinical with the GTx and STx for process development.

So really, it's a mix. We feel good where we are in the year and where we guided for the year in terms of instrument revenue as well. So it's within our expectations, a little bit higher than our expectations actually. And we feel good exactly as going into the year that it would be around here. Parmeet, did you want to take the second part?

Parmeet Ahuja

Yes. Julie, you pointed to our non-core revenue guidance. So of the $2 million royalty, we recognized $1.2 million through first half, $0.4 million in Q1 and $0.8 million in Q2. As you pointed out, CASGEVY beat market expectations this quarter, and we're starting to see real traction, which supports the remaining royalty.

And as we've discussed before, there can be quarter-to-quarter variability as CASGEVY ramps consistent with what Vertex has communicated in their -- on their earnings call. Fundamentally, we're excited about the continued progress with CASGEVY with significant growth sequentially and year-over-year. And as commercial sales continue to build, we will start to see the royalty revenue truly materialize in our P&L.

Maher Masoud

Can I add something there as well, Parmeet? So Julie, obviously, Vertex commented on their call. We did now have three consecutive quarters of 100 patient initiations, more patients infused so far in the first half than all of last year. We just don't want to comment on our partners and Vertex's programs. That's for them, but we are very excited about what we're seeing. So I'll leave it there.

Operator

Our next question comes from the line of Hannah Raiford of Stephens Inc.

Hannah Hefley

It's good to see instrument demand kind of stabilize, and it sounds like that was pretty much across the board. Are you still seeing any pockets of hesitancy around CapEx? Or do you feel like that headwind is kind of behind you?

Maher Masoud

Parmeet, let me take that. Yes. So we see stabilization, both on the instrument side and on the processing assembly side as well, PAs. We feel the headwinds that we had last year are behind us. And we don't see any more pockets of headwind demands in any way. So we feel good. This is a return back to stability and get back to growth in the second half, and it's exactly where we are.

I mean this is a good quarter for us. We have a good year ahead of us. It's exactly what we expect. We're seeing the funding exactly what we expected going into the year, stability there, it's come back. And we're growing from there. I mean we've done -- and we're seeing it across the board. If you look at our revenue beat, it was both on the SPL and non-SPL side as well. So a very good quarter for us. We don't see any pockets of headwinds ahead.

Parmeet Ahuja

Yes. And maybe to build on that a little bit, Maher. As we look ahead, Hannah, in our funnel we're continuing to expect instrument revenue to be a primary driver. And much like this quarter across both academic and industry with a healthy distribution across our instrument portfolio.

We certainly have had a recently announced partnership with Genentech that will play a role in the second half as well as the continued rollout of the DTx.

Hannah Hefley

Awesome. And then as it relates to that Genentech partnership, can we expect to see more of those coming up? How does this kind of change your strategy going forward? Could you just talk about what we can expect there?

Maher Masoud

Absolutely. Great question, Hannah. So it's -- the strategy is twofold. The SPLs are still a big driver of the future growth of this company. We now have two ways of working with industry, one with biotechs through the SPLs and through enterprise-level multi-partnership agreements with Genentech and other large pharma and large biotech, right? So it allows us to really now get into large pharma, which we've never done before.

We're able to monetize on a risk-adjusted basis, programs here on a multi-program basis, not just one program. So it's -- we feel good where we are, right? We have a good funnel for the SPLs for the rest of the year going into next year as well. We now have an ability to and a model that works very well with large pharma, which we look to continue to negotiate with other large pharmas. So this is a complementary basis. It's not one or the other. And this shows -- really shows the power of our platform.

This is a case where with Genentech specifically, we're supporting them with two of their clinical allo programs now as well as the preclinical research program. So it's a multi-platform agreement. It shows the power and strength of our platform. I keep reiterating that we are best-in-class. The investments we've made as well with the DTx where we now are the only company that has something that can take you from research all the way to commercial without needing any further scale-up, no one can do that.

That's us. So we feel very good where we are. SPLs are our future. These multi-partnership agreements are our future as well. It's -- we believe in the space. The cell therapy space has stabilized. We feel the future of the cell therapy space, and we're diversifying our revenues now throughout cell therapy. It's not just small or smaller biotechs. It's biotechs, large biotechs, large pharma, multiple ways through analytical capabilities as well with the SeQure acquisition, which was part of the Genentech partnership as well. So we feel very good about this, Hannah.

Operator

Our next question comes from the line of Matt Hewitt of Craig-Hallum Capital Group.

Matthew Hewitt

Congratulations on the progress made during the quarter. I'm curious regarding the Genentech agreement, how have the discussions with some of your other larger SPL customers changed, if at all? And as you go into that next round of discussions with those that maybe were in the pipeline, how do you decide who the better fit is as far as for SPL versus the multi-platform agreement?

Is there -- is it purely based on size? Is it the number of targets that the customer is looking at? Any color there would be helpful.

Maher Masoud

Yes. Very good question. So let me take the first part. It hasn't changed the tenor of conversation with any of the current SPL future partners in the funnel. All of those, for the most part, are those biotech companies. The Genentech deal is a multi-platform deal, right? It's across the entire spectrum of the electroporation side as well as the analytical SeQure side. That's the color where with Genentech that we would pursue with other larger biotechs or with large pharma as well.

It also allows us with the Genentech deal, we're able to monetize the value much further up in the relationship. That's something that, obviously, with the big biotechs, that's not a flavor for them, right? That's more of the Genentechs and those type of companies. So in essence, I say it again, Matt, we have a model now for both our SPL biotech companies as well as the Genentech and other large pharma, and we're pursuing those.

I mean we're speaking with other large pharma as well. We'll continue to do so. They take time to transpire. These are -- even with the SPLs. These are negotiations sometimes in discussions and working with them early can take 18 months to develop plus and that's part of our model, but we now have a way to work with what we always said, the large pharma model. So not concerned in any way that's going to change any of our current discussions. If there are any changes, it's always in a good way.

Matthew Hewitt

Got it. And then maybe shifting gears, you noted an uptick or at least some improvement in academic a couple of times in your prepared remarks. I'm just curious what you're seeing there. Obviously, the funding environment from an academic perspective, my sense remains pretty challenging. So the fact that you're seeing some improvement there, I think, bodes well. And I'm just curious your expectations over the remainder of the year for that market segment.

Maher Masoud

Yes, absolutely. So we're seeing on the academic side, we are seeing traction there. A lot of it is also related to -- these are academic that are taking clinical trials. So these are pursuing clinical trials. So these are GMP-based academic partners that we're working with, and we're seeing that traction. We've always said that. That's what's going to seed the future of biotechs, the future SPLs.

So we've made a conscious decision to go -- when we talked about going earlier in research, going earlier with the researchers. That's part of what we meant, and that's what we're seeing. And it's not a surprise to us. It was actually part of our execution plan going into this year. Let's go after -- let's diversify our revenue model. And that's one of the ways. So that's what you're seeing there, Matt.

It's really a way for us to capture the future SPLs. I'll say it, we always said it before, the only platform anybody should use for cell therapy is MaxCyte's platform. So we get in there early in the academic with these clinical trials that eventually will become future industry-sponsored companies and trials. They should be working with us, and that's what we're doing.

Operator

Our next question comes from the line of Mark Massaro of BTIG.

Unknown Analyst

This is Megan on for Mark. You touched on it a bit earlier, but with the $141.9 million in cash and investments on the balance sheet, what are you seeing in your inorganic deal pipeline?

Maher Masoud

In our inorganic deal pipe? So ask that question one more time, and I want to make sure we're clear what you're asking. Megan?

Unknown Analyst

Of course. So just really what -- with all the cash and investments on the balance sheet, what you're looking or like what you're seeing in the deal pipeline?

Maher Masoud

You mean in the M&A deal pipeline? So let me tell you how we look at our cash balance sheet. We have three ways of looking at this. We always invest in the organic growth of this company. That was the DTx. That's the continued investments for now in SeQure as well, building out their assays. That's first and foremost. We obviously always look for selective programs out there or potential transactions out there.

But again, very, very selective. And then there, we're always looking to return back value to our shareholders. So that's that $141 million that you're seeing there, that's what we did. That was evident by the buyback that was approved by the Board earlier this year, where, as Parmeet mentioned earlier, we've already repurchased $5.5 million worth in the buyback. But it is an investment in MaxCyte, first and foremost, being very selective and returning capital and really shareholder value back to our investors.

Unknown Analyst

Awesome. And then also just curious if you've seen any changes in the competitive environment over the past year.

Maher Masoud

Good question. We have not seen changes in the competitive environment. In fact, with the recent transaction that we announced right now, we displaced a competitor in the clinic. We're still the best-in-class platform. We develop -- we're continuing to invest in the products themselves and our ExPERT platform. It's not just the ExPERT DTx that you're seeing. We continue to create application workflows that are proprietary to MaxCyte.

These application workflows themselves are new product launches. These are things that we have that other companies do not have. We have a field-based scientific team. We have a scientific team internally. We know cell therapy better than any other company out there. So it's our platform, it's our scientists. We're not seeing any new competition, and we're displacing the competition both in academia and in industry now. So we feel very good where we are.

Operator

Our next question comes from the line of Dan Arias of Stifel.

Daniel Arias

Maher, you kind of alluded to it with the instrument commentary, but can you just maybe expand a little bit on the overall environment? I mean some of the comments that have been made across the space have just been suggestive of some improvement in biotech spending.

Would you sign on for seeing that yourselves? And what is the overall feel on just the state of affairs when it comes to spending and pipeline management overall?

Maher Masoud

Yes. Good question, Dan. The information you see out there and what we're seeing out there in terms of return back to biotech funding, it's a bit different than the industry we're in. So it's more outside of cell therapy. We're seeing more of a stabilization in cell therapy. It's not a return back to your 2020, 2021 years. That's not the case. But that's exactly what we expected going into the year, and that's what we're operating within. That's why we're not expecting to come back to those 2020, 2021 years.

We're actually diversifying our revenue model. We are launching new products. We're finding ways now to work with large pharma we've never done before. We're actually leaning into the cell therapy space. We don't need to come back to those 2020, 2021 to get back to the growth that we're getting back to. So it's not quite the same as what you're seeing out there in terms of funding for the bioprocessing or bioproduction market.

It's not as robust as that, but we don't need it to be. We're -- we know exactly where it is. We're not seeing headwind anymore. It's stabilized. It has not gone back to some of the numbers you're seeing for the other spaces, but that's -- we knew that going into the year, and we feel good about this year and even going into next year.

Daniel Arias

Okay. Maybe just as a follow-up, the inventory work down at the large account that you talked about, I think your largest customer, you said, has that run its course? Or is that a factor for the back half, too?

Maher Masoud

No, it has. It's largely run its course. That's why we feel good. We said going into this year, there was a headwind that we had in the first half. It's behind us now, and it will not have any effect going into the second half. I mean, Parmeet, anything to elaborate there?

Parmeet Ahuja

No, I think you answered that well.

Operator

Our next question comes from the line of Brendan Smith of TD Cowen.

Brendan Smith

Congrats on the quarter. Maybe just a quick follow-up to one of the previous questions on kind of the broader momentum within cell therapy. I mean we've heard from a few other tool guys this quarter that cell and gene therapy is maybe still lagging a bit behind other modalities. But to your point, I think things seem to have stabilized and maybe moving back in the right direction.

So I guess do you expect a material acceleration in some of these programs in the second half of this year and maybe demand with it? Or is that something we should maybe expect to be a little bit more 2027 weighted? Just kind of curious how you're seeing that funnel at this point.

Maher Masoud

Very good question, Brendan. That's more into 2027. We have the five programs. The beauty of our business model is that we sign these SPLs and these programs progress into the clinic. So these 14 clinical programs we have now, we still expect five that are moving into pivotal.

One has already moved into pivotal, is actually part of what we reported in Q1 as well. That's more into 2027 where we expect them to potentially even have an approved product in 2027, resulting from these five late-stage programs. So it's more -- I wouldn't say back half weighted. It's more going into 2027 where we see the impact of that.

Brendan Smith

Okay. Got it. That's helpful. And then I guess maybe more broadly, I just wanted to ask, in terms of SPL and potential new deal signings, we have seen some pretty convincing signs that some ex U.S. markets are leaning maybe even more aggressively into cell therapy, especially in APAC.

I guess is that something MaxCyte could potentially capitalize on? Are there any kind of caveats or considerations to an SPL with some of those kinds of partners? Just any incremental color on how you guys are thinking about that, too.

Maher Masoud

Yes. Great question, Brendan. That's something we began to look into a few years ago, and we knew where the space was going. We saw the investments in Asia Pacific, specifically in China. And we've created a presence there, and we're seeing some growth there, granted from a smaller base, but it's -- we're seeing healthy growth there.

And we continue to invest in Asia Pacific, specifically China, Japan, Korea, even India and Australia. We're investing there. And that's exactly right. We're seeing a lot of programs being initiated there with the hopes of then making it to the U.S. or to Europe. And we're working with those companies. We're beginning to build that infrastructure there.

We have a sales team and FAS team in Asia Pac. We have a general manager that's overseeing Asia Pacific for us as well. We're very cognizant of that. And we have a model for that. The same way we have a model in large pharma. The same way we have a model now with academia. We have a model where we're working with them in the clinic over there that will then transpire into future SPLs and partnerships when they broaden their horizons to the U.S. and to Europe.

Operator

Our next question comes from the line of Julie Simmonds of Panmure Liberum.

Julie Simmonds

Just another quick question following up on the instruments. I was just wondering, now you've got sort of multiple different instrument types in the market. Is there a big variation in the processing assembly revenue that comes from each of those?

Or is the expectation that DTx because it will be doing more -- you're selling sort of more lower-priced consumables. I'm just sort of trying to see if there's a mix effect that we might see there.

Maher Masoud

Let me take that, and then Parmeet, if you want to add to that. So the DTx has a higher pull-through of processing assembly revenue. That's in early research, both used for cell therapy and in vivo gene editing as well. We expect a higher pull-through on the DTx PAs. Obviously, the processing assemblies for your clinical, your GTx, that has -- that begins to ramp as these programs go further into the clinic, especially when they go to commercial. So it's a mix.

So you have from early research of DTx higher pull-through. You have the ATx and STx that has their pull-through, not quite as high as what the DTx would be. But obviously, they're at a higher price point as well when you're doing process optimization going to the clinic. And then your cGMP PAs, obviously, we can see right now from our largest customer have a significant and meaningful revenue for us.

As we begin to see more of these SPLs go through late stages, we're seeing right now, our model is proving itself. And as we see more programs get approved, which we believe will have at least one next year, potentially one next year, you're going to see more revenue growth from those PAs on the clinical side as well. So it's a mix, high pull-through early and then you have much higher cost PAs that have a high ramp as programs go to pivotal and then to commercial.

Parmeet Ahuja

Yes. It's -- just to maybe build on that, it's different price structure, obviously, right? The idea with the DTx is to get in early on the research side of things, we will have higher PA pull-through. But obviously, as Maher indicated, there are price differences there as programs then scale up further to clinical and further.

Julie Simmonds

Okay. And just on the SPL, I mean, I gather there's sort of still a pipeline of ones that you're discussing. You've historically talked about sort of three to five a year. I mean, does that still seem reasonable sort of taking Genentech slightly because it's a slightly different offering?

Maher Masoud

It is. In terms of licenses, we still -- three to five, as I think I mentioned on the last quarterly call, we sometimes will sign more than five as we've done a few years ago. Sometimes we'll sign less than three. But overall, three to five looking at the funnel is a healthy number. We still feel confident we can sign one to two even in the back half of the year that includes Genentech.

So we feel good where we are in terms of all the licenses that we're signing. It's more of the timing of where we are in the negotiations with the biotechs or even large pharma. So some years we might have more than five, some years more than three. But on average, you're going to have that three to five over the years.

Operator

I'm showing no further questions at this time. I'll now turn it back to Maher Masoud, CEO, for closing remarks.

Maher Masoud

Thank you, operator. And thank you, everyone, for joining us again. I look forward to speaking to you on the next quarterly call.

Operator

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.